The Gastroesophageal Reflux Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gastroesophageal Reflux Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroesophageal Reflux Disease Market.

Some of the key takeaways from the Gastroesophageal Reflux Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastroesophageal Reflux Disease treatment therapies with a considerable amount of success over the years. 
• Gastroesophageal Reflux Disease companies working in the treatment market are  HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others, are developing therapies for the Gastroesophageal Reflux Disease treatment 

• Emerging Gastroesophageal Reflux Disease therapies in the different phases of clinical trials are- IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others are expected to have a significant impact on the Gastroesophageal Reflux Disease market in the coming years.   
• In June 2022, Zydus Lifesciences was given permission by the Food and Drug Administration (FDA) to market Famotidine tablets in strengths of 20mg and 40mg. A histamine H2 receptor blocker called famotidine works by lowering stomach acid. The drug also relieves and prevents heartburn and other signs of acid reflux
• Fexuprazan is an experimental P-CAB used to treat EE, a chronic and progressive disease that affects millions of people in the United States. It’s intended to prevent proton pumps from secreting stomach acid. Proton pump inhibitors (PPIs), the current standard of care for EE, have been demonstrated to function more slowly whereas P-CABs block acid secretion more efficiently and long-term
• In October 2021, In order to licence its Fexuprazan gastroesophageal reflux medicine, Daewoong Pharmaceutical entered under a contract with Aghrass Healthcare Limited that could be valued 99.1 billion won ($83.7 million). According to the deal, the Jeddah, Saudi Arabia, company will market Fexuprazan in six Gulf Cooperation Council (GCC) nations: Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar by 2025, Bahrain, United Arab Emirates, and Saudi Arabia by 2024.

Gastroesophageal Reflux Disease Overview

The regurgitation of stomach contents into the oesophagus is what is known as gastroesophageal reflux disease (GERD), a chronic gastrointestinal ailment. It is one of the most often diagnosed digestive ailments in the US, with a prevalence of 20%, and it has a negative impact on quality of life and has a significant economic burden on both direct and indirect spending.

Get a Free Sample PDF Report to know more about Gastroesophageal Reflux Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-pipeline-insight

Emerging Gastroesophageal Reflux Disease Drugs Under Different Phases of Clinical Development Include:

• IN-C003: HK inno.N
• IN-C002: HK inno.N
• CKD-382: Chong Kun Dang Pharmaceutical
• IN-C004: HK inno.N
• AD-214: Addpharma
• JP-1366: Jeil Pharmaceuticals
• Naronapride: Renexxion
• Fexuprazan: Daewoong Pharmaceutical

Route of Administration

Gastroesophageal Reflux Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Gastroesophageal Reflux Disease Pipeline Therapeutics Assessment

• Gastroesophageal Reflux Disease Assessment by Product Type
• Gastroesophageal Reflux Disease By Stage and Product Type
• Gastroesophageal Reflux Disease Assessment by Route of Administration
• Gastroesophageal Reflux Disease By Stage and Route of Administration
• Gastroesophageal Reflux Disease Assessment by Molecule Type
• Gastroesophageal Reflux Disease by Stage and Molecule Type

DelveInsight’s Gastroesophageal Reflux Disease Report covers around 12+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gastroesophageal Reflux Disease product details are provided in the report. Download the Gastroesophageal Reflux Disease pipeline report to learn more about the emerging Gastroesophageal Reflux Disease therapies

Some of the key companies in the Gastroesophageal Reflux Disease Therapeutics Market include:

Key companies developing therapies for Gastroesophageal Reflux Disease are – AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co., Ltd, Eisai Co. Ltd., EndoStim, Inc., GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Novartis AG, Phathom Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Sebela Pharmaceuticals, SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Ltd, Teva Pharmaceuticals Industries Limited, and others.

Gastroesophageal Reflux Disease Pipeline Analysis:

The Gastroesophageal Reflux Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroesophageal Reflux Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroesophageal Reflux Disease Treatment.
• Gastroesophageal Reflux Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroesophageal Reflux Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroesophageal Reflux Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastroesophageal Reflux Disease drugs and therapies

Gastroesophageal Reflux Disease Pipeline Market Drivers

• Rising incidence of heartburn across the globe, technological advancements that allow for speedier diagnosis, are some of the important factors that are fueling the Gastroesophageal Reflux Disease Market.

Gastroesophageal Reflux Disease Pipeline Market Barriers

• However, loss of patent protection of several leading drugs, lack of approved therapies, and other factors are creating obstacles in the Gastroesophageal Reflux Disease Market growth.

Scope of Gastroesophageal Reflux Disease Pipeline Drug Insight    

• Coverage: Global
• Key Gastroesophageal Reflux Disease Companies:  HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
• Key Gastroesophageal Reflux Disease Therapies: IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
• Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
• Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers 

Request for Sample PDF Report for Gastroesophageal Reflux Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services